You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 6, 2011

Beating Cosmetic Product Registration Hurdles

Bangkok Post, Corporate Counsellor Column

On January 1, 2008, Asean member countries implemented the Asean Harmonization Cosmetics Regulation Scheme in order to harmonize a previously chaotic process. A multitude of confusing laws and procedures has now been transformed into a streamlined system with just a single category for cosmetic products and an efficient registration process.

The Thai Food and Drug Administration (FDA) implemented a new online cosmetic product registration system on November 1, 2010. Registration is now less time consuming and more environmentally friendly than under the previous paper-based system.

The FDA has also created a single product category, which forces some cosmetic companies to re-register their products. This is an important change from past practice, when there were three categories for cosmetic products.

According to the Society of Cosmetic Chemists of Thailand, the local cosmetic industry has been growing by 10 to 20 percent per year over the last ten years and is expected to see 30 percent growth in the domestic market in 2011. This domestic trend mirrors similar rapid growth in cosmetic imports.

Clearly, Thailand is becoming an extremely attractive place for cosmetic product distributors to do business. As the industry continues to expand, cosmetics distributors new to the market should be aware of possible hurdles that typically arise during the FDA product registration process. By preparing effectively, applicants will be able to save costs and bring their products to market quickly.

Product Name

Cosmetic products rely mainly on the name of the product to attract consumers. This has proven to be a very effective method for marketing the products, since this is the first element that consumers look at when electing to purchase a product.

Therefore, distributors need to take the utmost care when naming their products, prior to applying for product registration in Thailand. To avoid rejection by the FDA, each word in the product name must correctly reflect the objective of the product, and the words used must not mislead consumers.

One difficulty faced by companies is using product names that differ from the ingredients or the purpose of the product. For example, if the product name is “TRADENAME Tanning Body Lotion” but the product formula contains no ingredients that act as a tanning agent, this product will be declined registration by the FDA.

The manufacturer or importer must also exercise care in regard to the choice of a product name to avoid it being deemed an overclaim or use of homophonous words.

For example, a product used to combat wrinkles is called “TRADENAME Eraser Wrinkle Serum”. The word “eraser” will not be permitted for use in the product name because, in reality, the product cannot erase wrinkles. FDA officials would therefore deem the product name to be an overclaim.

Use of a homophonous word for a prohibited or improper word in a product name is also impermissible. An example of this is “Btox”, which is derived from the prohibited word “Botox”. “Btox” would be denied registration by the FDA because it is confusingly similar to the registered trademark BOTOX and is deemed an infringement.

Finally, scientific words such as “nano” are not recommended, as additional scientific or reliable supporting documents for those words must be submitted to the FDA to support the claimed correlation.

Formula

The use of a prohibited ingredient in a formula will definitely lead to a rejection by the FDA, and the manufacturer will be required to alter the product formula to secure FDA approval. Examples of prohibited ingredients commonly found in cosmetics are dimethylamine and diethylene glycol.

Some ingredients are authorized but restricted, and these ingredients are thus required to comply with special FDA rules. For example, a hair product formula for curling or straightening hair must not include tetraborates in an amount exceeding 8 percent, whereas a bath product formula must not exceed 18 percent (both are calculated in boric acid form).

A formula containing some specially controlled ingredients, especially natural extracts, must have a product safety document. For example, Citrus Reticulata Peel oil has no restrictions on the amount used in a formula. However, the total concentration of furocoumarin (found in this extract) in a finished cosmetic product must not exceed 1 ppm. Therefore, the company must certify the safety assessment of the product and provide an analysis of the amount of furocoumarin in the finished product.

FDA Cosmetic Category Codes

In the cosmetic registration process, an applicant is required to choose a cosmetic category code for each product from an FDA database known as the “Cosmetic Data Dictionary.”

For example, if the product is a facial makeup set consisting of compact face powder with foundation, sunscreen, and lip gloss, the cosmetic category code would be 12796. If this code is not clearly specified, the characteristics or product type may result in selection of the wrong cosmetic category code, which would lead to the application being rejected by the Examiner.

As the examples above illustrate, it is important that companies pay keen attention to the preparation of the registration of their product and advertising, as this will ensure a smooth and unhindered product launch.

 

RELATED INSIGHTS​ 

August 29, 2023
Since the June 9, 2022, delisting of all parts of the cannabis plant according to the Narcotics Code, there has been an explosion of cannabis dispensaries operating in Thailand. The Department of Thai Traditional and Alternative Medicine (DTTAM) has issued more than 12,000 cannabis dispensary licenses to businesses in Thailand. A license allows a dispensary to sell cannabis flowers legally. In addition, the DTTAM requests the cooperation of dispensaries in submitting monthly reports about the sourcing, selling, and inventory of cannabis flowers. The DTTAM may suspend the selling license of dispensaries that fail to submit these reports. Apart from the enforcement duties and administrative acts of the DTTAM, the enactment of the laws and regulations pertaining to cannabis seemed to be drastically winding down. One of the reasons was that Thailand had delays in the process of forming a new government following the general election of May 14, 2023. These delays dampened Thailand’s thriving cannabis industry. In particular, the industry has concerns about the uncertainty of the nascent cannabis law. On August 11, 2023, the Narcotics Control Division of the Thai Food and Drug Administration (FDA) posted the Draft Regulation Re: Application for Approval and Approval for Manufacture, Importation, Exportation, Distribution or Possession of Narcotics under Category 5 (Extracts from Cannabis or Hemp Plants Only). This may be the first regulation that the newly formed government implements with regard to cannabis extracts. Unlike the DTTAM’s enforcement activities, the Thai FDA requests that a domestic manufacturer, importer, exporter, or seller of cannabis extracts apply for a license. The Thai FDA, as the authority, will consider granting a license only in the following cases: For medical benefits; For commercial or industrial benefits; For the benefit of medical or scientific analysis or research; and For use by the government for preventing and
July 11, 2023
Enacted in 2009, Indonesia’s current Law on Health (Law No. 36/2009) is due for a refresh. The government realized that the law has not maintained its relevance when it comes to health trends such as digital health, which refers to the provision of health services online (also commonly known as telemedicine). While regulations and policy blueprints, such as Ministry of Health (MOH) Regulation No. 46/2017 concerning National E-Health Strategies, have addressed these shifting trends, Indonesia’s main health legislation has proved inadequate in this regard. For this reason, the government began making plans for an update to the law, and the first draft Omnibus Health Law was published in March 2023. The law addresses digital health and other important issues in today’s health landscape, and it seeks to promote the use of locally made health supplies. The draft Omnibus Health Law represents a notable step forward, but in its attempt to govern and regulate all aspects of health, there are also some issues in the draft that may overlap with some existing government regulations, such as provisions on Halal certification, compulsory licensing of patents, and addictive substances. This article outlines some of the draft law’s key aspects as well as some potential issues. Digital Health In addressing the growing health trend of telemedicine, the draft law confirms, reinforces, and fills gaps left by Indonesia’s three main regulations concerning telemedicine. namely, MOHR No. 20/2019 concerning Telemedicine, MOHR No. 24/2022 concerning Medical Records, and Medical Council Regulation No. 74/2020 concerning Telemedicine (MCR No. 74/2020). One of these regulations, MOH Regulation No. 20/2019, allows health service facilities to provide telemedicine services to other health service facilities. This covers telemedicine services related to radiology, electrocardiography, ultrasonography, and telemedicine consultancy services—including those that reflect developments in science and technology. This is the only regulation concerning
July 10, 2023
One of the more positive outcomes of the COVID-19 pandemic is that telemedicine has become remarkably important as an interactive system between patients and healthcare professionals. Thailand, which ranks near the top as a world medical hub, is a highly favored destination in Asia for expat workers. Currently, the Thai market has both Thai-based and foreign-based platforms with information about healthcare providers and telemedicine readily available. “Doctor Locator,” “Weed Map,” and “Find a Teeth Aligner Dentist” are examples of online platforms connecting patients with medical and telemedicine services. These digital platforms provide information about the location of specialized clinics, cannabis dispensaries, pharmacy stores, and orthodontic practitioners in Thailand. These platforms act as intermediaries between medical care businesses and consumers. As actual medical services are not offered or provided, these digital platforms do not have to be regulated under the Medical Facility Act of Thailand. However, healthcare digital platform services that act as an intermediary or conduit managing information used to connect medical clinics or cannabis dispensaries with patients or customers via a computer network are now regulated under the soon-to-be-implemented Royal Decree on Digital Platforms, regardless of whether payment is actually made via the platform. The regulatory authority for this is the Electronic Transactions Development Agency (ETDA). Under this royal decree, digital platform providers that intend to operate a digital platform service must notify the ETDA prior to initiating operations. The extent of the details to be included in the notification to the ETDA will be more comprehensive if the digital platform: has annual revenue (before expenses) for digital platform services within Thailand exceeding THB 1.8 million (approx. USD 51,200) for an individual operator or THB 50 million (approx. USD 1.42 million) for a corporate or entity operator; or has more than 5,000 users (on average) per month. Apart
July 10, 2023
On June 30, 2023, the Ministry of Health of Vietnam issued Circular No. 14/2023/TT-BYT stipulating the process and procedure for building bidding package prices for procurement of goods and services in the field of medical devices at public health facilities (“Circular 14”). Circular 14 took effect on July 1, 2023, and will be valid through the end of 2023. Circular 14 applies to the procurement of medical devices/equipment and their accessories, spare parts, and supplies, as well as related services of repair, maintenance, inspection, and calibration. Under Circular 14, there are three methods of determining the price of bidding packages: Collecting quotations provided by suppliers of goods and services in the field of medical devices. Surveying the winning bid prices of similar goods and services on the national bidding network system (https://muasamcong.gov.vn). Using the results of price appraisal of a competent state agency that conducts price appraisal, or a specialized price appraisal enterprise. Method (i) must be used first; the two remaining methods can be applied only after method (i) has been unsuccessful. If the investor/procuring entity uses two or more methods to determine the price of bidding packages, it can select the highest price that is suitable to its financial capacity and professional requirements. Circular 14 further sets out the specific step-by-step process to build prices for procuring products and services in the field of medical devices/equipment. Transitional Provision For bidding packages that have already approved a contractor selection plan before July 1, 2023, the approved contractor selection plan will be followed. For bidding packages for which a contractor selection plan has been submitted by the investor/procuring entity but the plan has not yet been approved, the competent person can decide on the approval of the submitted plan or can request the investor/procuring entity to rebuild the bidding